Literature DB >> 19302806

Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration.

Elaine Amaral Leite1, Cristiane dos Santos Giuberti, Alberto J A Wainstein, Ana Paula D L Wainstein, Luiz G V Coelho, Angela M Q Lana, Paulo R Savassi-Rocha, Mônica Cristina De Oliveira.   

Abstract

AIMS: The objective of this work was to evaluate the acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin (SpHL-CDDP), after their intraperitoneal administration in male and female mice. MAIN
METHODS: After single administration of free CDDP (5,10,and 20 mg/kg) or SpHL-CDDP (7,12,30,45 and 80 mg/kg), the body weight was recorded and the LD(50) was calculated. Blood samples were collected for biochemical and hematological analysis. Kidneys, liver, spleen and bone marrow were removed to histopathological examination. KEY
FINDINGS: Mice treated with high doses of free CDDP showed a greater loss of body weight and more delayed recovery time than those treated with SpHL-CDDP. The LD(50) values for SpHL-CDDP treatment for male and female mice groups were 2.7 and 3.2 fold higher, respectively, than that obtained for free CDDP. The red and white blood cells counts and quantification of hemoglobin and hematocrit presented no change upon administration of SpHL-CDDP treatment. Free CDDP treatment, however, did lead to an appearance of mild anemia and a reduction in total white blood cell counts. As regards nephrotoxicity, it was observed that free CDDP treatment caused pronounced alterations in the blood urea and creatinine levels of mice. In contrast, these parameters were slightly altered only after SpHL-CDDP treatment at a dose of 30 mg/kg. Microscopic analysis of kidneys from mice treated with SpHL-CDDP showed no morphological alteration. Concerning hepatotoxicity, no histopathological alteration was observed after both treatments. SIGNIFICANCE: These findings reveal that SpHL-CDDP can eliminate CDDP-induced toxicity and is thus a promising candidate for intraperitoneal chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302806     DOI: 10.1016/j.lfs.2009.02.002

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Cystatin C - a fast and reliable biomarker for glomerular filtration rate in head and neck cancer patients.

Authors:  Edwin Bölke; Gisela Schieren; Stephan Gripp; Gerald Steinbach; Matthias Peiper; Klaus Orth; Christiane Matuschek; Maximilian Pelzer; Guido Lammering; Ruud Houben; Christina Antke; Lars Christian Rump; Rodrigo Mota; Peter Arne Gerber; Patrick Schuler; Thomas K Hoffmann; Ethelyn Rusnak; Derik Hermsen; Wilfried Budach
Journal:  Strahlenther Onkol       Date:  2011-02-24       Impact factor: 3.621

2.  Paeonol, a major compound of moutan cortex, attenuates Cisplatin-induced nephrotoxicity in mice.

Authors:  Hyojung Lee; Gihyun Lee; Hyunseong Kim; Hyunsu Bae
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-19       Impact factor: 2.629

3.  An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis.

Authors:  Tatiana G Ribeiro; Juçara R Franca; Leonardo L Fuscaldi; Mara L Santos; Mariana C Duarte; Paula S Lage; Vivian T Martins; Lourena E Costa; Simone O A Fernandes; Valbert N Cardoso; Rachel O Castilho; Manuel Soto; Carlos A P Tavares; André A G Faraco; Eduardo A F Coelho; Miguel A Chávez-Fumagalli
Journal:  Int J Nanomedicine       Date:  2014-11-19

4.  Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity.

Authors:  Elaine A Leite; Cristina M Souza; Alvaro D Carvalho-Júnior; Luiz G V Coelho; Angela M Q Lana; Geovanni D Cassali; Mônica C Oliveira
Journal:  Int J Nanomedicine       Date:  2012-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.